Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

In this paper, we propose novel non-MMSE criterion based recursive algorithms, namely quaternion recursive maximum correntropy criterion (QRMCC) and quaternion recursive maximum Versoria criterion ...

Quaternion-based machine learning algorithms have emerged as a promising candidate for four dimensional (4D) signal processing, which utilize 4D signal dimensions’ correlations for estimation purposes ...

For example, recursive splicing must now be taken into accountwhen evaluating mutations that disrupt gene expression and produce adysfunctional or non-functional protein.

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection ...

Specifically, Recursion uses an artificial intelligence (AI)-based algorithm in a virtual lab that tests clinical compounds on a library of human genes.

Recursion Pharma's AI-driven drug development and promising pipeline of candidates could potentially lead to a notable shift in share price. Read more here.

Recursion raised over $500 million in its IPO, making it the sixth-largest biotech-focused IPO of the decade. Read why I think RXRX stock is not for everyone.